Market revenue in 2023 | USD 110.1 million |
Market revenue in 2030 | USD 244.5 million |
Growth rate | 12.1% (CAGR from 2023 to 2030) |
Largest segment | Shingrix |
Fastest growing segment | Shingrix |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Shingrix, Zostavax |
Key market players worldwide | Merck & Co Inc, Skye Bioscience Inc Ordinary Shares, Green Cross Health Ltd, Barinthus Biotherapeutics PLC ADR, CanSino Biologics Inc Class H, GSK PLC, GeneOne Life Science |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to shingles vaccine market will help companies and investors design strategic landscapes.
Shingrix was the largest segment with a revenue share of 89.74% in 2023. Horizon Databook has segmented the Canada shingles vaccine market based on shingrix, zostavax covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada shingles vaccine market , including forecasts for subscribers. This country databook contains high-level insights into Canada shingles vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account